HealthDay on MSN

Early Use of Higher-Efficacy Therapies Recommended for Moderate-to-Severe Crohn Disease

Early use of higher-efficacy therapies is recommended for patients with moderately to severely active Crohn disease (CD), ...
Medical Dialogues

Real-World Evidence in Psoriatic Arthritis: PRO-SPIRIT Study - Video

In the video, Dr. Nicola J. Gullick, a Consultant Rheumatologist in Coventry and one of the investigators on the PRO-SPIRIT ...

Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease locatio…

Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless ...
The Manila Times

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
EMBO Press

Decoding non-coding SNPs: systems genomics modelling dissects the heterogeneity of IBD

The iSNP systems genomics pipeline models how non-coding SNPs cumulatively impact cellular signalling and gene regulatory networks, revealing patient-specific mechanisms linking disease-associated ...